Skip to main content

Table 3 Characteristics of patients with HR positive and HR negative tumor

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

 

HR* positive tumor

HR negative tumor

Factors

BP group

N = 202

Non-BP group

N = 28

P-value||

BP group

N = 60

Non-BP group

N = 27

P-value||

Age (yr, median, range)

46 (28–77)

50.5 (33–68)

NS**

43.5 (25–69)

50 (30–67)

NS

PS*** (ECOG ≥ 2)

9/138 (6.5%)

0/16 (0%)

NS

1/28 (3.6%)

2/11 (18.2%)

NS

Pre-menopausal

66/144(45.8%)

4/18 (22.2%)

0.057

13/32 (40.6%)

3/12 (25%)

NS

Post-menopausal

78/144(54.2%)

14/18 (77.8%)

 

19/32 (59.4%)

9/12 (75%)

 

HER2 positive

44 (21.8%)

12 (42.9%)

0.015

28 (46.7%)

11 (40.7%)

NS

DFI† (months, median, range)

27.5 (0–230)

26 (82.1%)

NS

18.5 (0–86)

18 (0–174)

NS

Initial stage IV

44 (21.8%)

4 (14.3%)

NS

17 (28.8%)

7 (25.9%)

NS

Adjuvant treatment

      

   Radiotherapy

82 (40.6%)

15 (53.6%)

NS

29 (48.3%)

12 (44.4%)

NS

   Chemotherapy

139 (68.8%)

21 (75%)

NS

37 (61.7%)

17 (63%)

NS

   Hormonal therapy

114 (56.4%)

17 (60.7%)

NS

13 (21.7%)

4 (14.8%)

NS

Metastatic sites

      

   Visceral (liver, lung)

80 (39.6%)

18 (64.3%)

0.013

36 (60%)

19 (70.4%)

NS

   LNs‡

87 (43.1%)

12 (42.9%)

NS

32 (53.3%)

18 (66.7%)

NS

   Soft tissue

57 (28.2%)

8 (28.6%)

NS

21 (35%)

12 (44.4%)

NS

   Bone only

73 (36.1%)

6 (21.4%)

NS

8 (13.3%)

2 (7.4%)

NS

   Weight bearing bone involvement

174 (86.6%)

13 (46.4%)

< 0.001

51 (85%)

12 (44.4%)

< 0.001

   Sum of metastatic sites (range)

2 (1–6)

3 (1–5)

NS

3 (1–5)

3 (1–6)

NS

Cycles of palliative chemotherapy

  

NS

  

NS

   1

27 (13.4%)

4 (14.3%)

 

9 (15%)

4 (14.8%)

 

   2

43 (21.3%)

3 (10.7%)

 

10 (16.7%)

10 (37%)

 

   ≥ 3

116 (57.4%)

17 (60.7%)

 

41 (68.3%)

12 (44.4%)

 

Palliative AI§ use

159 (78.7%)

21 (75%)

NS

9 (15%)

2 (7.4%)

NS

Palliative anti-HER2 therapy

35/44 (79.5%)

10/12 (83.3%)

NS

23/28 (82.1%)

10/11 (90.9%)

NS

Disease progression in bone

96 (47.5%)

10 (35.7%)

NS

23 (38.3%)

6 (22.2%)

NS

SREs (except the first event)

59 (29.2%)

4 (14.3%)

NS

15 (25%)

4 (14.8%)

NS

  1. Abbreviations: *, hormone receptor; **, not significant; ***, performance status; †, disease free interval; ‡, lymph nodes;
  2. § aromatase inhibitor; ||, P-value was obtained via chi-square test except variables of age and DFI which were obtained through Mann-Whitney U test.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us